Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

A concerning relationship between cancer chemotherapy and adverse neurological ... DNA crosslinking agents—and cytosine arabinoside (cytarabine; an antimetabolite) were distinctly toxic to ...

The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the ...

The survival benefit was consistent regardless of the chemotherapy backbone used. For patients treated with fludarabine, cytarabine, idarubicin (FAI) chemotherapy combined with uproleselan, the hazard ...

Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...

A total of 58 consecutive patients were enrolled in the study. All patients were evaluable for efficacy and tolerability. Patient baseline characteristics, summarized in Table 1, were similar ...

and cytarabine consolidation chemotherapy. This will be followed by up to three years of maintenance therapy with Vanflyta as a single agent. Overall survival is the primary endpoint for these arms.